Timing Effect of Adenosine-Directed Immunomodulation on Mouse Experimental Autoimmune Uveitis

Area of Science:

• Immunology
• Ophthalmology
• T cell biology

Background:

• Adenosine regulates immune responses.
• Previous studies showed adenosine deaminase inhibited experimental autoimmune uveitis (EAU) by targeting Th17 cells.
• Adenosine receptor antagonists were investigated to modulate Th17 responses.

Purpose of the Study:

• To investigate the therapeutic potential of adenosine receptor antagonists in EAU.
• To determine the effect of A2AR antagonist SCH 58261 on Th17 responses in EAU.
• To elucidate the mechanisms underlying adenosine-mediated regulation of Th17 cells in EAU.

Main Methods:

• Induced EAU in mice.
• Treatment with A2AR antagonist SCH 58261 at different disease stages.
• Assessment of EAU development and severity.
• Analysis of Th17 cell responses and gamma-delta T cell activation.

Main Results:

• SCH 58261 inhibited EAU when administered during active disease but not during quiescent stages.
• Adenosine acts as a costimulator for gamma-delta T cell activation, essential for Th17 responses.
• During active EAU, adenosine synergizes with high cytokine levels to augment gamma-delta T cell and Th17 responses.
• During quiescent EAU, low cytokine levels prevent adenosine from enhancing gamma-delta T cell activation.

Conclusions:

• Blockade of adenosine signaling, particularly via A2AR antagonists, can suppress pathogenic Th17 responses in EAU.
• The therapeutic efficacy of adenosine-based treatments is dependent on the disease stage and existing immune status.
• Targeting the synergistic interaction between adenosine and inflammatory cytokines during active disease offers a potential therapeutic strategy for EAU.